“Panel Discussion: Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients”, Can Hematol Today, vol. 1, no. S10, Oct. 2022, doi: 10.58931/cht.2022.1S1029.